CLDI · Calidi Biotherapeutics, Inc.
$1.34
+0.02 (+1.52%)
At close · Aug 31
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company estimates that based on the Company's liquidity resources, there is substantial doubt about the Company's ability to continue as a going concern within 12 months from the date of issuance of these unaudited condensed consolidated financial statements.”View the 10-Q filed Aug 13, 2026
Market Cap
$3.41M
Shares
2.58M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Andrew Jackson | Chief Financial Officer | $516,880 |
| Allan Camaisa | Former Chief Executive Officer and Chairman of the Board | $509,121 |
| Wendy Pizarro Campbell | Chief Legal Officer, Chief Administrative Officer, Chief Diversity Officer and Corporate Secretary | $484,015 |
| Boris Minev | President, Medical & Scientific Affairs | $417,731 |
| Eric Poma | Chief Executive Officer and Director | — |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| George Ng | Prior President, Chief Operating Officer and Current Director | $731,343 |
| Tony Kalajian | Prior Chief Accounting Officer and Interim Chief Financial Officer Boris Minev, Ph.D. | $507,015 |
| Allan Camaisa | Former Chief Executive Officer and Chairman of the Board | $436,512 |
| Boris Minev | President, Medical & Scientific Affairs | $400,096 |
| Wendy Pizarro Campbell | Chief Legal Officer, Chief Administrative Officer, Chief Diversity Officer and Corporate Secretary | $295,404 |
| Wendy Pizarro | Chief Legal Officer, Chief Administrative Officer, Chief Diversity Officer and Corporate Secretary | $295,404 |
| Andrew Jackson | Chief Financial Officer | $71,635 |
| Eric Poma | Chief Executive Officer and Director | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| George Ng | Prior President, Chief Operating Officer and Current Director | $2,460,880 |
| Wendy Pizarro | Chief Legal Officer, Chief Administrative Officer, Chief Diversity Officer and Corporate Secretary | $1,569,277 |
| Allan Camaisa | Chief Executive Officer and Chairman of the Board | $1,537,818 |
| Tony Kalajian | Prior Chief Accounting Officer and Interim Chief Financial Officer Boris Minev, Ph.D. | $1,314,362 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Corazon (Corsee) D. Sanders, Ph.D. | member of the Audit Committee of the Board | Appointed | 2026-06-23 |
| Scott Leftwich | Class III director | Appointed | 2026-04-02 |
| Andrew Jackson | Corporate Secretary | Appointed | 2025-09-19 |
| Wendy Pizarro Campbell | Chief Legal Officer | Terminated | 2025-09-19 |
| Boris Minev | President, Medical and Scientific Affairs | Terminated | 2025-08-14 |
| Boris Minev | President, Medical and Scientific Affairs | Terminated | 2025-07-25 |
| Eric Poma | CEO | Appointed | 2025-04-23 |
| Eric Poma | Class I director | Appointed | 2025-04-23 |
| Allan Camaisa | Chairman of the Board | Resigned | 2025-04-23 |
| Allan Camaisa | Chief Executive Officer | Resigned | 2025-04-23 |
| Dr. George Peoples | director | Appointed | 2024-06-26 |
| David LaPre | director | Resigned | 2024-05-16 |
| David LaPre | director | Appointed | 2023-12-12 |
| Thomas Vecchiolla | director | Resigned | 2023-12-12 |
| Alfonso Zulueta | director | Resigned | 2023-12-05 |
| Andrew Jackson | Chief Financial Officer | Appointed | 2023-10-30 |
| Tony Kalajian | interim Chief Financial Officer | Resigned | 2023-10-27 |
| Tony Kalajian | Chief Accounting Officer | Resigned | 2023-10-27 |
| Dr. Heehyoung Lee | Director | Resigned | 2023-10-16 |
| George K. Ng | President and Chief Operating Officer | Resigned | 2023-09-19 |
| George K. Ng | President and Chief Operating Officer | Appointed | 2023-09-19 |
| James Schoeneck | Class II director | Appointed | 2023-09-19 |
| Heehyoung Lee | Class I director | Appointed | 2023-09-19 |
| Alfonso Zulueta | Class I director | Appointed | 2023-09-19 |
| Thomas Vecchiolla | Class II director | Appointed | 2023-09-19 |
Key facts
CIK
1855485
CUSIP
320703408
13F (30d)
15 filings
15 filers
Visit website
Investor relations